JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Y-320 is a new phenylpyrazoleanilide immunomodulator [1].
Immunotherapy refers to treatment of disease by suppressing, inducing or enhancing an immune response.
Y-320 is a new phenylpyrazoleanilide immunomodulator. Y-320 inhibited IL-17 production by CD4 T cells induced by IL-15 with IC50 values of 20-60 nM [1].
In type II collagen-induced arthritis (CIA) mice, oral administration of Y-320 (0.3-3 mg/kg) reduced IL-17 mRNA expression and significantly inhibited the development of joint destruction and arthritis. The combination of Y-320 with anti-murine tumor necrosis factor-α (TNF-α) monoclonal antibody exhibited a synergistic effect. In cynomolgus monkeys, Y-320 (0.3-1 mg/kg) relieved CIA. These results suggested that Y-320 could be a useful candidate for therapy of rheumatoid arthritis (RA) [1].
Reference:[1]. Ushio H, Ishibuchi S, Oshita K, et al. A new phenylpyrazoleanilide, y-320, inhibits interleukin 17 production and ameliorates collagen-induced arthritis in mice and cynomolgus monkeys. Pharmaceuticals (Basel), 2013, 7(1): 1-17.